NCT07573982尚未招募不适用
Safety and Feasibility Trial of Ultrasonic Debris Clearance to Promote Brain Resilience
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 15
- 试验地点
- 1
研究概览
简要总结
This pilot study will evaluate the safety, tolerability, and feasibility of Ultrasonic Debris Clearance (UDC), a noninvasive low-intensity focused ultrasound intervention, in amyloid-positive adults who are asymptomatic but at risk for Alzheimer's disease, or who have mild cognitive impairment or mild dementia. The study is designed to test whether repeated UDC sessions can be delivered safely and feasibly in this population, while also exploring efficacy via biomarkers and clinical measures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Physician-reported amyloid positivity diagnosed by amyloid positron emission tomography (PET) OR historic CSF positivity of Abeta42, total tau, or phosphorylated tau OR positivity of plasma pTau-
- •Age ≥ 18 years. No gender/sex, racial, or ethnic preference. Subjects greater than 60 years of age will be assumed to be non-pregnant based on age and expected post-menopausal status. Female subjects under the age of 60 will complete a two-step assessment of pregnancy status (a self-reported assessment of menopause that proceeds to a urine human chorionic gonadotropin (hCG) test to confirm non-pregnancy, if the participant is not post-menopausal).
- •CDR Scale score less than or equal to 1.0, consistent with mild, very mild, or no dementia.
- •Ability and willingness to comply with the study procedures (six sessions sitting in a procedure chair for up to one hour for the procedure, with an ultrasound device placed on their scalp; additional time for the MRI assessment, blood draws, and cognitive assessments).
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Dementia of moderate or higher severity (CDR > 1.0) 2.
- •Intracranial tumors, acute or chronic hemorrhage (beyond petechiae/microhemmorhage), or other current or historic central nervous system specific pathology. Baseline MRI studies will be screened by the protocol director to ensure no exclusionary intracranial pathology is present.
- •Any other comorbidity that would prevent adequate interpretation of the study results per the treatment team (e.g. congenital brain malformations without clinical importance) 2.
- •Ultrasound attenuators along the ultrasound beam path (metal, air, or bulky calcification) including thick hair or related adornments that cannot be undone for the study (e.g. turbans, dreadlocks, hairweaves/wigs) that would prevent adequate ultrasound gel coupling of the device to the scalp or could trap air in the ultrasound beam path.
- •Contraindications to MRI (unknown device, claustrophobia) or metallic hardware in the head that prevent adequate MRI visualization of the brain 2.
- •Allergy or similar intolerance to the materials used for ultrasound device coupling (ultrasound gel, silicone) 2.
- •Receipt of anti-amyloid monoclonal antibody therapy within 6 months prior to screening 2.
- •Moderate or greater depressive symptoms at screening, defined as a Patient Health Questionnaire-9 (PHQ-9) total score >=
- •Clinically significant suicidal ideation or behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) 2.
- •Clinically significant hematologic abnormalities, defined as hematocrit < 35% for male or < 32% for female, absolute neutrophil cell count < 1500/uL, absolute lymphocyte count < 900/uL, or platelet count < 120,000/uL 2.
- •Clinically significant hepatic, renal, respiratory, cardiovascular, or metabolic disease that increases risk or interferes with interpretation, defined as ALT/AST/ALP > 1.5 ULN, or eGFR < 50 mL/min/1.73m2, or recent MI/unstable angina/HF/cardiomyopathy within 6 months, 2.
- •Significant bradycardia(<50/min) or tachycardia (>100/min) 2.
- •Poorly controlled BP 2.
- •Uncontrolled diabetes, defined as HbA1c > 7.5 2.
- •Active clinically significant infection or other systemic illness affecting the CNS
研究者
Raag Airan
Associate Professor of Radiology
Stanford University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
RISS Block for Enhanced Recovery After Video-Assisted Thoracoscopic SurgeryNCT07462273Ningbo University90
尚未招募
2 期
A Clinical Study Comparing Methods Used to Clean Root Canals and Reduce InfectionCTRI/2026/01/102509Dr. Nikita Agarwal51
尚未招募
不适用
Monitoring Disease Activity in Patients With Takayasu Arteritis With the OMERACT Takayasu Ultrasound Score (OTUS)Takayasu Arteritis (TAK)NCT07571577IRCCS San Raffaele100
尚未招募
Phase 3 4
Ability of Serratus Anterior Plane block in reducing post operative pain killer requirement after breast removal surgeryCTRI/2024/03/064147JLN Medical college60
招募中
不适用
Evaluation of the Effect of Using Ultrasound Robots for Breast Cancer Screening: A Multicenter, Parallel-group, Cluster Randomized Controlled TrialBreast CancerNCT07331363Huazhong University of Science and Technology70,000